Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment

P. Vici, G. Viola, S. Rossi, C. Botti, C. Vitucci, D. Sergi, F. R. Ferranti, E. Saracca, L. Di Lauro, S. Corsetti, P. Foggi, S. I S Fattoruso, M. Lopez

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Results from randomized trials evaluating taxane versus non-taxane containing regimens in adjuvant breast cancer treatment indicate an advantage in DFS and OS for the taxane-arms, but the best schedule of administration, in combination with anthracyclines or in sequence, is still a debated issue, even if the sequential strategy appears to be less toxic. Up to now, the majority of clinical trials employed the "standard" sequence, with anthracycline-based combinations first, followed by taxanes. Few small phase II trials evaluated the reverse sequence, with taxanes administered first, most of them in metastatic or neoadjuvant setting, suggesting efficacy and lower toxicity. An important issue to be considered is the hypothesized differences in the ability of the drugs to induce cross-resistance to each other, as suggested by data of a preclinical study, and from clinical study with a cross-over design; results of these trials suggest that the best strategy would be to administer a taxane prior to an anthracycline, also according to the Norton and Simon hypothesis. Moreover, trials evaluating the best sequence of anthracyclines and taxanes in adjuvant breast cancer setting are of small sample size, and an adequately powered randomized phase III trial is needed before definitive conclusions are reached.

Original languageEnglish
Pages (from-to)453-456
Number of pages4
JournalClinica Terapeutica
Volume159
Issue number6
Publication statusPublished - Nov 2008

Fingerprint

Taxoids
Anthracyclines
Breast Neoplasms
Poisons
Sample Size
Cross-Over Studies
Appointments and Schedules
Clinical Trials
Pharmaceutical Preparations
taxane

Keywords

  • Adjuvant treatment
  • Anthracyclines
  • Sequence
  • Taxanes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vici, P., Viola, G., Rossi, S., Botti, C., Vitucci, C., Sergi, D., ... Lopez, M. (2008). Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment. Clinica Terapeutica, 159(6), 453-456.

Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment. / Vici, P.; Viola, G.; Rossi, S.; Botti, C.; Vitucci, C.; Sergi, D.; Ferranti, F. R.; Saracca, E.; Di Lauro, L.; Corsetti, S.; Foggi, P.; Fattoruso, S. I S; Lopez, M.

In: Clinica Terapeutica, Vol. 159, No. 6, 11.2008, p. 453-456.

Research output: Contribution to journalArticle

Vici, P, Viola, G, Rossi, S, Botti, C, Vitucci, C, Sergi, D, Ferranti, FR, Saracca, E, Di Lauro, L, Corsetti, S, Foggi, P, Fattoruso, SIS & Lopez, M 2008, 'Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment', Clinica Terapeutica, vol. 159, no. 6, pp. 453-456.
Vici P, Viola G, Rossi S, Botti C, Vitucci C, Sergi D et al. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment. Clinica Terapeutica. 2008 Nov;159(6):453-456.
Vici, P. ; Viola, G. ; Rossi, S. ; Botti, C. ; Vitucci, C. ; Sergi, D. ; Ferranti, F. R. ; Saracca, E. ; Di Lauro, L. ; Corsetti, S. ; Foggi, P. ; Fattoruso, S. I S ; Lopez, M. / Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment. In: Clinica Terapeutica. 2008 ; Vol. 159, No. 6. pp. 453-456.
@article{08169f07637347639ae5fc82c0214467,
title = "Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment",
abstract = "Results from randomized trials evaluating taxane versus non-taxane containing regimens in adjuvant breast cancer treatment indicate an advantage in DFS and OS for the taxane-arms, but the best schedule of administration, in combination with anthracyclines or in sequence, is still a debated issue, even if the sequential strategy appears to be less toxic. Up to now, the majority of clinical trials employed the {"}standard{"} sequence, with anthracycline-based combinations first, followed by taxanes. Few small phase II trials evaluated the reverse sequence, with taxanes administered first, most of them in metastatic or neoadjuvant setting, suggesting efficacy and lower toxicity. An important issue to be considered is the hypothesized differences in the ability of the drugs to induce cross-resistance to each other, as suggested by data of a preclinical study, and from clinical study with a cross-over design; results of these trials suggest that the best strategy would be to administer a taxane prior to an anthracycline, also according to the Norton and Simon hypothesis. Moreover, trials evaluating the best sequence of anthracyclines and taxanes in adjuvant breast cancer setting are of small sample size, and an adequately powered randomized phase III trial is needed before definitive conclusions are reached.",
keywords = "Adjuvant treatment, Anthracyclines, Sequence, Taxanes",
author = "P. Vici and G. Viola and S. Rossi and C. Botti and C. Vitucci and D. Sergi and Ferranti, {F. R.} and E. Saracca and {Di Lauro}, L. and S. Corsetti and P. Foggi and Fattoruso, {S. I S} and M. Lopez",
year = "2008",
month = "11",
language = "English",
volume = "159",
pages = "453--456",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "6",

}

TY - JOUR

T1 - Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment

AU - Vici, P.

AU - Viola, G.

AU - Rossi, S.

AU - Botti, C.

AU - Vitucci, C.

AU - Sergi, D.

AU - Ferranti, F. R.

AU - Saracca, E.

AU - Di Lauro, L.

AU - Corsetti, S.

AU - Foggi, P.

AU - Fattoruso, S. I S

AU - Lopez, M.

PY - 2008/11

Y1 - 2008/11

N2 - Results from randomized trials evaluating taxane versus non-taxane containing regimens in adjuvant breast cancer treatment indicate an advantage in DFS and OS for the taxane-arms, but the best schedule of administration, in combination with anthracyclines or in sequence, is still a debated issue, even if the sequential strategy appears to be less toxic. Up to now, the majority of clinical trials employed the "standard" sequence, with anthracycline-based combinations first, followed by taxanes. Few small phase II trials evaluated the reverse sequence, with taxanes administered first, most of them in metastatic or neoadjuvant setting, suggesting efficacy and lower toxicity. An important issue to be considered is the hypothesized differences in the ability of the drugs to induce cross-resistance to each other, as suggested by data of a preclinical study, and from clinical study with a cross-over design; results of these trials suggest that the best strategy would be to administer a taxane prior to an anthracycline, also according to the Norton and Simon hypothesis. Moreover, trials evaluating the best sequence of anthracyclines and taxanes in adjuvant breast cancer setting are of small sample size, and an adequately powered randomized phase III trial is needed before definitive conclusions are reached.

AB - Results from randomized trials evaluating taxane versus non-taxane containing regimens in adjuvant breast cancer treatment indicate an advantage in DFS and OS for the taxane-arms, but the best schedule of administration, in combination with anthracyclines or in sequence, is still a debated issue, even if the sequential strategy appears to be less toxic. Up to now, the majority of clinical trials employed the "standard" sequence, with anthracycline-based combinations first, followed by taxanes. Few small phase II trials evaluated the reverse sequence, with taxanes administered first, most of them in metastatic or neoadjuvant setting, suggesting efficacy and lower toxicity. An important issue to be considered is the hypothesized differences in the ability of the drugs to induce cross-resistance to each other, as suggested by data of a preclinical study, and from clinical study with a cross-over design; results of these trials suggest that the best strategy would be to administer a taxane prior to an anthracycline, also according to the Norton and Simon hypothesis. Moreover, trials evaluating the best sequence of anthracyclines and taxanes in adjuvant breast cancer setting are of small sample size, and an adequately powered randomized phase III trial is needed before definitive conclusions are reached.

KW - Adjuvant treatment

KW - Anthracyclines

KW - Sequence

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=58849133796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849133796&partnerID=8YFLogxK

M3 - Article

C2 - 19169608

AN - SCOPUS:58849133796

VL - 159

SP - 453

EP - 456

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 6

ER -